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COMMIT trials. METHODS: A combined decision tree and
Markov model was constructed. Since existing evidence indicates
similar long-term outcomes after STEMI and NSTEMI, data
from the long-term NSTEMI CURE trial was combined with 1-
month data from CLARITY and COMMIT to model the effect
of treatment up to one year. The risk of death, MI and stroke in
an untreated population and long-term survival were derived
from the Swedish hospital and death registers. The model was
run separately for the two STEMI trials. A payer perspective was
chosen for the main analysis, focusing on direct medical costs.
Costs for Sweden, Germany and France were based on published
sources and were converted to 2005 Euros. Effectiveness was
measured as the number of life-years gained (LYG) from clopi-
dogrel treatment. RESULTS: Using a patient cohort with the
same characteristics and event rates as the CLARITY popula-
tion, adding clopidogrel to aspirin treatment for up to one year
resulted in 0.14 LYG. In Sweden and France, this strategy was
dominant with estimated cost savings of €110 and €370, respec-
tively. In Germany, clopidogrel treatment had an incremental
cost-effectiveness ratio (ICER) of €120/LYG. Using data from the
COMMIT study, clopidogrel treatment resulted in 0.19 LYG at
an incremental cost of €530 in Sweden, €540 in France and €790
in Germany. The corresponding ICERs were €2760/LYG,
€2760/LYG and €4130/LYG, respectively. CONCLUSIONS:
Treatment of STEMI patients with clopidogrel for up to one year
is cost-effective in all three European countries studied, with pre-
dicted ICERs well below generally accepted thresholds.
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OBJECTIVE: Pacemaker implantation is an established
approach to bradycardia due to sinoatrial node disease or 
atrioventricular block. A new kind of pacing system (managed
ventricular pacing), has been developed recently to avoid 
unnecessary pacing in the right ventricle. The objective is to eval-
uate the long term clinical and economic consequences, associ-
ated with the use of Adapta pacemakers, (which allow for
managed ventricular pacing) versus the standard dual chamber
pacemakers (DDDR) in a Spanish Hospital (Valencia General
Hospital), where pacemakers are implanted through ambulatory
surgery. Costs and beneﬁts were discounted at 3%. METHODS:
A lifetime discrete event simulation model was adapted to the
Spanish setting, simulating clinical evolution of bradycardia,
after a pacemaker implantation. Pairs of identical patients are
created, and one receives Adapta while the other a DDDR. Clin-
ical and utility data were obtained from published trials (MOST,
PASE) Distributions of ventricular pacing are based on data col-
lected during trials of these devices. Cost data came from Valen-
cia General Hospital costs database. Age and gender population
data were obtained from the Spanish Registry of Pacemakers
from the Spanish Society of Cardiology. RESULTS: Based on 100
replications of a hypothetical cohort, treating patients with
Adapta versus dual chamber pacemakers results in mean a saving
of €397 per patient. Adapta implantation is predicted to result
in a 65.4% decrease in heart failure hospitalization, a 16.5%
decrease in atrial ﬁbrillation, and an 11% reduction in the
number of strokes experienced. The model predicts an increase
of 0.29 QALYs per patient treated with managed ventricular
pacing; the Adapta device is dominant compared to DDDR.
CONCLUSIONS: Based on these estimates use of MVP vs. dual
chamber devices, in patients with bradycardia is an efﬁcient
strategy in the Spanish setting, providing better long-term clini-
cal and economic outcomes.
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OBJECTIVES: Although the importance of hypertension as a
risk factor for cardiovascular disease (CVD) is well know, blood
pressure remains uncontrolled in a signiﬁcant part of patients.
The aim of this study was to assess the cost-effectiveness of
adding olmesartan, a angiotensin-II-antagonist, to treatment in
patients with uncontrolled hypertension. Belgium was used as a
case country. METHODS: A Markov model with a 10-year time
horizon using 6-month cycles was developed in MSExcel.
Depending on age, smoking status, systolic blood pressure (SBP),
and total cholesterol, fatal CVD risk (cardiac death, fatal stroke)
was calculated using the SCORE equation for patients without
a history of CVD and using the Framingham equation for
patients with a history of CVD (18%). Non-fatal risk was indi-
rectly calculated based on landmark primary prevention trials.
Clinical data were obtained from the Belgian 12-week Olme-R3-
study (Olmetec Real-life Responder Rate-study) in which 4130
patients with uncontrolled hypertension were started on olmes-
tartan (10, 20 or 40 mg at the physician’s discretion-74%
received 20 mg) assuming that effects are maintained over 10-
years. Direct costs from the Belgian payers’ perspective were
included. Ofﬁcial sources for cost of events and cost of drugs
were used. The unit costs of olmesartan, 10, 20 and 40 mg are
respectively €0.70, €0.50 and €0.63 (10 mg more expensive due
to pack-size). Annual discounting of 3% was applied on cost and
effects. RESULTS: At 12 weeks, adding olmesartan decreased
SBP with 22.47 mmHg (95%CI 22.00–22.94 mmHg—baseline
SBP 160 mmHg) and decreased the number of antihypertensive
drugs needed. The cost of antihypertensive treatment increased
from €0.54 to €0.73 (part olmesartan €0.53) per day. Applying
the observed SBP effect to the 10-year model results in a 
incremental cost-effectiveness ratio of €9813/LYG (95%CI
€9568/LYG-€10,073/LYG). CONCLUSIONS: Adding olmesar-
tan to antihypertensive treatment in patients with uncontrolled
hypertension seems cost-effective from the perspective of the
health care payer.
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OBJECTIVES: Patients presenting a cluster of cardiometabolic
risk factors (CMRF) are at increased risk of developing cardio-
vascular disease (CVD). One possible clustering is the metabolic
syndrome (MS). We investigated the long-term outcomes associ-
ated with MS in a Swiss population. METHODS: A computer
simulation model was developed to project life expectancy (LE)
